BYSI Stock BYSI is expected to report earnings to fall -29% to -75 cents per share on July 10

A.I.dvisor
at Tickeron.com
06/12/24
Loading...
BYSI - BeyondSpring
BeyondSpring Earnings Graph
Q1'23
Est.
$-0.75
Q4'22
Missed
by $0.30
Q3'22
Missed
by $0.21
Q2'22
Missed
by $0.13
Q1'22
Est.
$-0.23
The last earnings report on December 31 showed earnings per share of -58 cents, missing the estimate of -28 cents. P/B Ratio (0.000) is normal, around the industry mean (12.430). P/E Ratio (0.000) is within average values for comparable stocks, (148.069). BYSI's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.460). Dividend Yield (0.000) settles around the average of (0.065) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (218.643). With 37.50K shares outstanding, the current market capitalization sits at 92.11M.
View a ticker or compare two or three
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of cancer therapies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
28 Liberty Street
Phone
+1 646 305-6387
Employees
67
Web
https://www.beyondspringpharma.com